MX2023013714A - Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1). - Google Patents
Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1).Info
- Publication number
- MX2023013714A MX2023013714A MX2023013714A MX2023013714A MX2023013714A MX 2023013714 A MX2023013714 A MX 2023013714A MX 2023013714 A MX2023013714 A MX 2023013714A MX 2023013714 A MX2023013714 A MX 2023013714A MX 2023013714 A MX2023013714 A MX 2023013714A
- Authority
- MX
- Mexico
- Prior art keywords
- protein antibodies
- accessory protein
- receptor accessory
- receptor
- antibodies
- Prior art date
Links
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 title abstract 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 title 1
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción proporciona nuevos anticuerpos contra IL-1RAcP.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21175216 | 2021-05-21 | ||
| EP21192805 | 2021-08-24 | ||
| PCT/EP2022/063774 WO2022243536A1 (en) | 2021-05-21 | 2022-05-20 | Anti il-1 receptor accessory protein antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013714A true MX2023013714A (es) | 2024-01-16 |
Family
ID=82067490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013714A MX2023013714A (es) | 2021-05-21 | 2022-05-20 | Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1). |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220411517A1 (es) |
| EP (1) | EP4341290A1 (es) |
| JP (1) | JP2024520338A (es) |
| KR (1) | KR20240013138A (es) |
| AU (1) | AU2022278636A1 (es) |
| CA (1) | CA3220913A1 (es) |
| IL (1) | IL308602A (es) |
| MX (1) | MX2023013714A (es) |
| SA (1) | SA523451603B1 (es) |
| WO (1) | WO2022243536A1 (es) |
| ZA (1) | ZA202310247B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250060305A (ko) | 2022-09-21 | 2025-05-07 | 사노피 바이오테크놀로지 | 인간화 항-il-1r3 항체 및 사용 방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005512044A (ja) | 2001-12-03 | 2005-04-28 | アブジェニックス・インコーポレーテッド | 結合特性に基づく抗体分類 |
| EP2935334A4 (en) | 2012-12-21 | 2016-10-26 | Cellerant Therapeutics Inc | ANTIBODIES THAT FIX TO MEMBRANE-RELATED IL1 RAPID |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| EP3313887A2 (en) | 2015-06-26 | 2018-05-02 | MAB Discovery GmbH | Monoclonal anti-il-1racp antibodies |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| WO2018071910A2 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| JP7657440B2 (ja) | 2017-06-12 | 2025-04-07 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート |
| CN111246882A (zh) | 2017-08-01 | 2020-06-05 | 希望之城 | 抗il1rap抗体 |
| DK3802608T3 (da) | 2018-05-24 | 2025-06-10 | Janssen Biotech Inc | Anti-cd3-antistoffer og anvendelser deraf |
| JP7428661B2 (ja) | 2018-05-30 | 2024-02-06 | 中外製薬株式会社 | Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド |
| CN112638946A (zh) * | 2018-08-16 | 2021-04-09 | 坎塔吉亚有限责任公司 | 抗il1rap抗体组合物 |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| CN110041428B (zh) | 2019-03-28 | 2022-01-28 | 河北农业大学 | 一种抗人白介素-1受体辅助蛋白的单链抗体及其应用 |
| CA3143211A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| EP4211165A1 (en) | 2020-09-14 | 2023-07-19 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof |
| MX2023007611A (es) | 2020-12-23 | 2023-07-12 | Cantargia Ab | Anticuerpo anti-il1rap. |
| EP4288457A2 (en) | 2021-02-05 | 2023-12-13 | Boehringer Ingelheim International GmbH | Anti-il1rap antibodies |
| CN114835799A (zh) | 2021-05-28 | 2022-08-02 | 百奥赛图江苏基因生物技术有限公司 | Il1rap基因人源化非人动物的构建方法及应用 |
| CN116574189A (zh) | 2023-01-30 | 2023-08-11 | 北京智仁美博生物科技有限公司 | 针对人il-36r和/或人il-1r3的多种抗体及其用途 |
| CN116284401B (zh) | 2023-02-20 | 2024-09-24 | 中国人民解放军军事科学院军事医学研究院 | 人源抗il-1r3抗体及其应用 |
| CN116143926A (zh) | 2023-03-22 | 2023-05-23 | 南京融捷康生物科技有限公司 | 一种抗IL1RAcP的单域抗体及其用途 |
-
2022
- 2022-05-20 AU AU2022278636A patent/AU2022278636A1/en active Pending
- 2022-05-20 CA CA3220913A patent/CA3220913A1/en active Pending
- 2022-05-20 KR KR1020237041664A patent/KR20240013138A/ko active Pending
- 2022-05-20 IL IL308602A patent/IL308602A/en unknown
- 2022-05-20 JP JP2023571611A patent/JP2024520338A/ja active Pending
- 2022-05-20 MX MX2023013714A patent/MX2023013714A/es unknown
- 2022-05-20 EP EP22730754.3A patent/EP4341290A1/en active Pending
- 2022-05-20 WO PCT/EP2022/063774 patent/WO2022243536A1/en not_active Ceased
- 2022-05-20 US US17/664,349 patent/US20220411517A1/en not_active Abandoned
-
2023
- 2023-11-02 ZA ZA2023/10247A patent/ZA202310247B/en unknown
- 2023-11-13 US US18/507,579 patent/US12043669B2/en active Active
- 2023-11-21 SA SA523451603A patent/SA523451603B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220411517A1 (en) | 2022-12-29 |
| IL308602A (en) | 2024-01-01 |
| EP4341290A1 (en) | 2024-03-27 |
| WO2022243536A9 (en) | 2023-12-28 |
| ZA202310247B (en) | 2025-03-26 |
| CA3220913A1 (en) | 2022-11-24 |
| JP2024520338A (ja) | 2024-05-24 |
| SA523451603B1 (ar) | 2025-04-29 |
| US20240190977A1 (en) | 2024-06-13 |
| WO2022243536A1 (en) | 2022-11-24 |
| KR20240013138A (ko) | 2024-01-30 |
| US12043669B2 (en) | 2024-07-23 |
| AU2022278636A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002880S1 (es) | Estuche de auriculares. (divisional solicitud 202000595) | |
| CL2020003361S1 (es) | Cargador. | |
| MY205933A (en) | Sirp-alpha binding proteins and methods of use thereof | |
| JOP20210194A1 (ar) | مستقبلات المستضدات الخيمرية لـ gprc5d وخلايا تعبر عنها | |
| PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| WO2020127377A9 (en) | Bifunctional anti-pd-1/il-7 molecule | |
| MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| WO2020010079A3 (en) | Anti-steap1 antigen-binding protein | |
| WO2019177883A3 (en) | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease | |
| CL2019002232S1 (es) | Automóvil. | |
| CA188474S (en) | Sponge | |
| CL2020001201S1 (es) | Automóvil. | |
| CL2020000174S1 (es) | Automóvil. | |
| WO2019117685A3 (ko) | 항-igf1r 항체 및 그 용도 | |
| EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
| MX2020009465A (es) | Anticuerpos anti-klk5 y metodos de uso. | |
| AU2021359068A8 (en) | Caninized antibodies to canine interleukin-31 receptor alpha | |
| TWD202667S (zh) | 閘道器 | |
| JOP20200295A1 (ar) | أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها | |
| MX2022007158A (es) | Anticuerpos anti-ly6g6d y metodos de uso. | |
| EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
| MX2021000797A (es) | Anticuerpos agonistas de cd226. | |
| ZA202310247B (en) | Anti il-1 receptor accessory protein antibodies | |
| MX2020010092A (es) | Variantes de anticuerpo c-terminales. |